CAPRICOR THERAPEUTICS INC

Capricor’s CFO and EVP buy low, sell high on June 25, showing strong insider confidence in Deramiocel’s promising phase‑II results and FDA review prospects.

Insider buying shows confidence in Capricor’s Deramiocel breakthrough, potentially boosting the stock when the FDA decision arrives. Discover why investors should watch this biotech closely.

Capricor Therapeutics insider sale shows disciplined, rule‑compliant equity management amid bullish DMD pipeline momentum and rising investor sentiment.

Capricor insiders’ strategic 10‑b‑5‑1 trades reveal confidence in future upside despite a negative P/E and early‑stage pipeline. Read the detailed analysis.